title: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin.
abstract: BACKGROUND
  Adenocarcinoma of the pancreas remains one of the most difficult malignancies to treat. Its incidence has steadily increased over the past four decades, and its prognosis is still dismal. AIM To assess tumor control and the palliative benefit of 5-fluorouracil (5-FU), cisplatin (CDDP), and radiotherapy in patients with advanced pancreatic cancer.
  
  
  METHODS
  Systemic chemotherapy consisted of 5-FU (600 mg/m ), given as a 22-hour infusion on days 1 to 5, and CDDP (100 mg/m ), given as a 90-minute infusion on day 2. Treatment courses were repeated identically on day 21. Radiotherapy was delivered using megavolt irradiation of 25-MV photons with a two- or four-field isocentric technique.
  
  
  RESULTS
  Twenty-seven patients were treated with this radiochemotherapy (RCT). Twenty-one patients (78%) completed initial treatment. The median dose of radiation therapy delivered was 42.5 Gy. At the time of evaluation (1 month after the end of the RCT), no grade 4 (WHO) toxicity was observed; 12 patients had improved or stable body weight; pain was improved for 20 patients, with 11 experiencing no pain; and analgesic consumption decreased for 18 patients, of whom 11 stopped intake. The clinical benefit response was 7/27 (26%). Median survival and time to progression were, respectively, 9 and 4.4 months.
  
  
  CONCLUSIONS
  This RCT regimen had a good impact on clinical benefit in locally advanced pancreatic carcinoma, without severe side effects.
authors.affiliation: Department of Radiation Oncology, Val d'Aurelle-Paul Lamarque Cancer Institute, Montpellier, France. azria@valdorel.fnclcc.fr
authors.forename: David
authors.initials: D
authors.lastname: Azria
authors.forename: Marc
authors.initials: M
authors.lastname: Ychou
authors.forename: William
authors.initials: W
authors.lastname: Jacot
authors.forename: Simon
authors.initials: S
authors.lastname: Thezenas
authors.forename: Claire
authors.initials: C
authors.lastname: Lemanski
authors.forename: Pierre
authors.initials: P
authors.lastname: Senesse
authors.forename: Patricia
authors.initials: P
authors.lastname: Prost
authors.forename: René
authors.initials: R
authors.lastname: Delard
authors.forename: Bruno
authors.initials: B
authors.lastname: Masson
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Dubois
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil